Biontech SE

Form 420-F13G

Insider Trading (Form 4)

See all →
NASDAQ
BNTX
Biontech SE
Form 4: BioNTech CFO Reports Stock Option and PSU Transactions
BioNTech SE's Chief Financial Officer, Ramon Zapata Gomez, has reported the acquisition of stock options and performance share units.
NASDAQ
BNTX
Biontech SE
Form 4: BioNTech Officer Reports Stock Option and PSU Grants
BioNTech SE reports on May 12, 2026, that Chief Legal Officer and Chief Business Officer Ryan James Timothy Patrick was granted stock options and performance share units.
NASDAQ
BNTX
Biontech SE
Form 4: BioNTech COO Acquires Shares and Performance Units
BioNTech SE Chief Operating Officer Sierk Poetting has acquired company shares and performance units through option exercises and PSU grants.
NASDAQ
BNTX
Biontech SE
Form 4: BioNTech SE: Executive Stock Option and PSU Grant
BioNTech SE reports the grant of stock options and performance share units to Chief People Officer Kylie Jimenez.
NASDAQ
BNTX
Biontech SE
Form 4: BioNTech COO Sells Shares Under 10b5-1 Plan
BioNTech SE Chief Operating Officer Sierk Poetting has sold 50,000 ordinary shares through a pre-arranged 10b5-1 trading plan.
NASDAQ
BNTX
Biontech SE
425: BioNTech Secures 81.74% of CureVac Shares in Exchange Offer
BioNTech SE announced the successful satisfaction of the minimum condition for its exchange offer for CureVac N.V., with 81.74% of shares tendered.

Schedule 13G - Passive Investments

NASDAQ
BNTX
Biontech SE
SCHEDULE: BioNTech Major Shareholder Ownership Update
ATHOS KG, AT Impf GmbH, and Thomas Maier maintain a 40.2% beneficial ownership stake in BioNTech SE.
NASDAQ
BNTX
Biontech SE
SCHEDULE 13G/A: BioNTech SE Founders Reaffirm Substantial Ownership in Latest SEC Filing
Medine GmbH and Prof. Ugur Sahin, M.D. have jointly filed an amendment to their Schedule 13G, reaffirming their substantial beneficial ownership in BioNTech SE, with Prof. Sahin holding 17.6% and Medine GmbH holding 16.7% of the ordinary shares.